requires all the answers
Get the complete picture before choosing treatment.
Guideline-recommended testing for solid tumors1-13
ALK ATM BRAF BRAF V600E BRAF V600K BRCA1 BRCA2 CDK12 EGFR ERBB2 (HER2) ESR1 FGFR2 FGFR3 IDH1 KIT KRAS MET MSI NRAS NTRK PDGFRA PIK3CA RET ROS1
There are FDA-approved therapies available for all solid tumors with NTRK fusions and MSI status.
Current as of September 2020
Targeted treatment improves outcomes.
Patients with targetable alterations experience higher response rates to targeted therapy vs. immunotherapy.1
Liquid biopsy offers critical advantages over tissue testing.
Leading with liquid-first testing can help inform clinical decisions faster than tissue.
You might also be interested in:
Enhance Your Practice with Guardant360 CDx
Make Guardant360 CDx a routine part of care
Precise and Rapid Advanced Cancer Treatment Selection
How Guardant360 CDx can help determine the most appropriate treatment
Optimizing Advanced Cancer Treatment Using Complete Genomic Profiling
The latest webinar from our Peer Education Program